NCT00125359View on ClinicalTrials.gov

Study of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions
Carcinoma, Non-small-cell Lung
Interventions
DRUG

erlotinib and bexarotene

Daily Erlotinib 150mg and daily bexarotene oral capsules 400mg.

Trial Locations (2)

10029

Mount Sinai School of Medicine, New York

03756

Norris Cotton Cancer Center, Lebanon

Sponsors
All Listed Sponsors
collaborator

Ligand Pharmaceuticals

INDUSTRY

collaborator

Genentech, Inc.

INDUSTRY

lead

Konstantin Dragnev

OTHER

NCT00125359 - Study of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung Cancer | Biotech Hunter | Biotech Hunter